Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,116 | 784 | 99.5% |
| Education | $68.77 | 8 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,987 | 88 | $0 (2024) |
| ABBVIE INC. | $1,572 | 115 | $0 (2024) |
| Amgen Inc. | $1,026 | 60 | $0 (2024) |
| PFIZER INC. | $987.85 | 52 | $0 (2024) |
| Allergan, Inc. | $914.08 | 72 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $823.61 | 44 | $0 (2024) |
| Lilly USA, LLC | $815.41 | 44 | $0 (2024) |
| Novo Nordisk Inc | $735.28 | 44 | $0 (2024) |
| Merck Sharp & Dohme LLC | $649.73 | 49 | $0 (2022) |
| GlaxoSmithKline, LLC. | $596.72 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,284 | 69 | ABBVIE INC. ($263.27) |
| 2023 | $1,481 | 76 | ABBVIE INC. ($341.10) |
| 2022 | $1,940 | 102 | ABBVIE INC. ($432.24) |
| 2021 | $1,721 | 98 | AbbVie Inc. ($353.66) |
| 2020 | $2,024 | 115 | AstraZeneca Pharmaceuticals LP ($397.06) |
| 2019 | $1,770 | 91 | AstraZeneca Pharmaceuticals LP ($398.49) |
| 2018 | $1,863 | 111 | AstraZeneca Pharmaceuticals LP ($411.85) |
| 2017 | $2,102 | 130 | Merck Sharp & Dohme Corporation ($249.29) |
All Payment Transactions
792 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: UROLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $9.56 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $8.18 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $120.09 | General |
| Category: PAIN | ||||||
| 11/04/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $8.67 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Respiratory | ||||||
| 10/09/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: RESPIRATORY | ||||||
| 10/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.60 | General |
| Category: NEUROSCIENCE | ||||||
| 09/20/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: NEUROSCIENCE | ||||||
| 09/18/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: Endocrinology | ||||||
| 09/17/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $7.87 | General |
| Category: NEUROSCIENCE | ||||||
| 09/10/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $115.59 | General |
| Category: RESPIRATORY | ||||||
| 09/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Respiratory | ||||||
| 08/22/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: Neuroscience | ||||||
| 08/22/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Insomnia | ||||||
| 08/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.68 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: Respiratory | ||||||
| 07/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Obesity | ||||||
| 07/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.75 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $8.27 | General |
| Category: NEUROSCIENCE | ||||||
| 07/09/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,338 | 3,127 | $245,549 | $75,759 |
| 2022 | 20 | 1,627 | 4,311 | $312,135 | $96,521 |
| 2021 | 19 | 1,479 | 4,152 | $288,436 | $122,535 |
| 2020 | 19 | 1,522 | 4,401 | $239,735 | $107,836 |
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 234 | 542 | $106,232 | $21,341 | 20.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 840 | $23,520 | $15,166 | 64.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 114 | 193 | $26,827 | $6,819 | 25.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 143 | 143 | $39,182 | $6,020 | 15.4% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 20 | 20 | $6,300 | $5,643 | 89.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 70 | 70 | $5,320 | $5,032 | 94.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 205 | 348 | $11,484 | $4,526 | 39.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 207 | 376 | $3,816 | $3,028 | 79.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 72 | 72 | $2,664 | $1,976 | 74.2% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 90 | 173 | $4,325 | $1,628 | 37.6% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2023 | 11 | 11 | $1,573 | $1,439 | 91.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 21 | 21 | $7,371 | $1,182 | 16.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 35 | 35 | $1,295 | $974.05 | 75.2% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Facility | 2023 | 11 | 11 | $1,419 | $373.60 | 26.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 36 | 48 | $2,832 | $372.96 | 13.2% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 11 | 12 | $853.00 | $164.55 | 19.3% |
| 81003 | Automated urinalysis test | Office | 2023 | 25 | 28 | $168.00 | $61.60 | 36.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 22 | 184 | $368.00 | $11.78 | 3.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 269 | 655 | $128,380 | $25,519 | 19.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 17 | 1,440 | $34,560 | $24,132 | 69.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 157 | 291 | $40,286 | $10,887 | 27.0% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 25 | 25 | $7,875 | $6,951 | 88.3% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 249 | 425 | $14,025 | $5,506 | 39.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 137 | 137 | $35,898 | $5,237 | 14.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 75 | 75 | $5,700 | $5,060 | 88.8% |
About Dr. Oksana Melnyk, M.D
Dr. Oksana Melnyk, M.D is a Family Medicine healthcare provider based in Little Rock, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437192283.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Oksana Melnyk, M.D has received a total of $14,185 in payments from pharmaceutical and medical device companies, with $1,284 received in 2024. These payments were reported across 792 transactions from 57 companies. The most common payment nature is "Food and Beverage" ($14,116).
As a Medicare-enrolled provider, Melnyk has provided services to 5,966 Medicare beneficiaries, totaling 15,991 services with total Medicare billing of $402,651. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Little Rock, AR
- Active Since 06/13/2006
- Last Updated 05/21/2008
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1437192283
Products in Payments
- FARXIGA (Drug) $1,253
- JARDIANCE (Drug) $869.03
- VRAYLAR (Drug) $650.76
- UBRELVY (Drug) $647.60
- JANUVIA (Drug) $411.30
- QULIPTA (Drug) $406.20
- TRULICITY (Drug) $386.99
- Prolia (Biological) $385.43
- NURTEC ODT (Drug) $341.93
- VYVANSE (Drug) $311.64
- XIFAXAN (Drug) $310.55
- SYMBICORT (Drug) $297.84
- LINZESS (Drug) $257.20
- TRELEGY ELLIPTA (Drug) $256.57
- Otezla (Drug) $249.23
- QUVIVIQ (Drug) $239.47
- SOLIQUA 100/33 (Biological) $228.00
- CHANTIX (Drug) $225.88
- AREXVY (Drug) $218.03
- BREZTRI (Drug) $205.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Little Rock
Dr. Kevin Roberts, Md, MD
Family Medicine — Payments: $133,330
Dr. Derek Lewis, M.d, M.D
Family Medicine — Payments: $117,470
Dr. Harold Betton, M.d, M.D
Family Medicine — Payments: $23,468
Benjamin Mcdonald, D.o, D.O
Family Medicine — Payments: $13,868
Dr. J . Timothy Hodges, Md, MD
Family Medicine — Payments: $13,633
Dr. Thomas Moore, Md, MD
Family Medicine — Payments: $13,080